Uipath Inc. (PATH)

NYSE · Broad Market

Latest Move · 2026-02-24

+1.40%
Modest bounce after steep selloff; no fresh catalyst identified

UiPath stock rose 1.4%. The company launched new agentic AI solutions for the healthcare industry designed to address administrative and financial bottlenecks for clinicians and healthcare administrators. Recent analyst activity shows mixed sentiment. Royal Bank of Canada set a price target of $14.00 on February 11, 2026. Zacks Research downgraded the stock from strong-buy to hold on February 6, 2026, while Wall Street Zen downgraded from strong-buy to buy on February 8, 2026. Barclays raised its price target from $16.00 to $18.00 with an equal weight rating on January 12, 2026. Insider selling occurred, with CFO Ashim Gupta selling 67,468 shares on January 5 and CEO Daniel Dines selling 45,000 shares on January 26, 2026.

Read full analysis

Previous Move

-5.23%
UiPath extends multi-week selloff as downtrend accelerates ahead of March earnings
2026-02-23

Frequently Asked Questions

Why did Uipath Inc. stock move today?

UiPath stock rose 1.4%. The company launched new agentic AI solutions for the healthcare industry designed to address administrative and financial bottlenecks for clinicians and healthcare administrators. Recent analyst activity shows mixed sentiment. Royal Bank of Canada set a price target of $14.00 on February 11, 2026. Zacks Research downgraded the stock from strong-buy to hold on February 6, 2026, while Wall Street Zen downgraded from strong-buy to buy on February 8, 2026. Barclays raised its price target from $16.00 to $18.00 with an equal weight rating on January 12, 2026. Insider selling occurred, with CFO Ashim Gupta selling 67,468 shares on January 5 and CEO Daniel Dines selling 45,000 shares on January 26, 2026.

What does Uipath Inc. do?

UiPath is an enterprise software company specializing in robotic process automation (RPA) — tools that help large organizations automate repetitive digital tasks like data entry and compliance workflows. The company has been expanding into AI-powered 'agentic automation,' including its recent WorkFusion acquisition targeting financial services and new healthcare solutions announced at ViVE 2026. Shares have fallen roughly 30% since early February amid CEO and CFO insider share sales and multiple analyst downgrades, with the March 11 earnings call as the next potential inflection point.

AI-generated analysis · Not financial advice · Always do your own research
Disclaimer & Terms · Privacy Policy